Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children

Pediatric Critical Care Medicine

Volumn 12, Issue 6, 2011, Pages

  Giachetto, Gustavo A ^a   Telechea, Héctor M ^a   Speranza, Noelia ^a   Oyarzun, Mireille ^a   Nanni, Luciana ^b   Menchaca, Amanda ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b Centro Hospitalario Pereira Rossell   (Uruguay)

Author keywords

critical ill children; pharmacokinetics pharmacodynamics; vancomycin

Indexed keywords

VANCOMYCIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STAPHYLOCOCCUS INFECTION;

EID: 81155127325     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181fe4047     Document Type: Article

References (31)

1. Xue Ma X, Galiana A, Pedreira W, et al: Community-acquired methicillin-resistant Staphylococcus aureus. Uruguay Emerging Infectious Disease 2005; 11:973-976
2. Bonino A, Gnesetti A, Pujadas M, et al: Infecciones por Staphylococcus aureus meticilino resistente adquirido en la comunidad: Analisis de una poblacion pediatrica asistida en el Hospital Policial de Uruguay 2004. Arch Pediatr Urug 2007; 78:41-47
3. Atencion Pediatrica Pautas de diagno stico, tratamiento y prevencion. Sixth Edition. Montevideo, Oficina del libro AEM, 2007, pp 161-169
4. Giachetto G, Telechea H, Speranza N, et al: Uso de vancomicina en servicios de internacio n pediatrica del Centro Hospitalario Pereira Rossell. Arch Pediatr Urug 2006; 77: 118-124
5. Telechea H, Speranza N, Lucas L, et al: Evolucio n del consumo de antibio ticos y de la susceptibilidad antimicrobiana en el Centro Hospitalario Pereira Rossell en la era del Staphylococcus aureus meticilino resistente. Rev Chil Infect 2009; 26:413-419
6. Rotschafer JC, Crossley K, Zaske DE, et al: Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22:391-394
7. James A, Koren G, Milliken J, et al: Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31:52-54
8. Ginovart Galiana G, Mangues Bafalluy MA, Demestre Guasch X, et al: Comportamiento farmacocinetico de la vancomicina en neonatos de edad postconcepcional 32 semanas Propuesta de una pauta de dosificacion. An Esp Pediatr 1996; 45:167-171
9. Pea F, Porreca L, Baraldo M, et al: High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45:329-335
10. Cruciani M, Gatti G, Lazzarini L, et al: Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-869
11. Rane A: Drug disposition and action in infants and children. In: Pediatric Pharmacology Therapeutic Principles in Practice. Second Edition. Yaffe SJ, Aranda JV (Eds). Philadelphia, WB Saunders, 1992, pp 10-21
12. Gous AG, Dance MD, Lipman J, et al: Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23:678-682
13. Pou L, Rossell M, Lopez R, et al: Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996; 18:149-153
14. Thomas M, Steele R: Monitoring serum vancomycin concentrations in children: Is it necessary? Pediatr Infect Dis J 1998; 17: 351-353
15. Machado JKK, Feferbaum R, Albuquerque Diniz EM, et al: Monitoring the treatment of sepsis with vancomycin in term newborn infants. Rev Hosp Clin Fac Med S Paulo 2001; 56:17-24
16. Tan WH, Brown N, Kelsall AW, et al: Dose regimen for vancomycin not needing serum peak levels' Arch Dis Child Fetal Neonatal Ed 2002; 87:F214-F216
17. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12
18. Craig WA: The role of pharmacodynamics in effective treatment of community-acquired pathogens. AVdanced Stud Med 2002; 2:126-134
19. Rybak M: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(Suppl 1):35-39
20. Frymoyer A, Hersh A, Benet L, et al: current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28:398-402
21. Moise-Border PA, Forrest A, Birmingham MC, et al: Pharmacodynamics of vancomycin and others antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-942
22. Soriano A, Marco F, Martínez J, et al: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus. Bacteriemia Clin Infect Dis 2008; 46:193-200
23. Hidayat LK, Hsu D, Quist R, et al: High-dose Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Infections Arch Intern Med 2006; 166:2138-2144
24. Lodise TP, McKinnon PS, Swiderski L, et al: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423
25. Rybak M, Lomaestro B, Rotschafer J, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98
26. Pardo L, Machado V, Mollerach M, et al: Characteristics of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains isolated from skin and soft-tissues infections in Uruguay. Int J Microbiol 2009; 2009:472126
27. Palacio R, Alonso R, Romero S, et al: Costos de las infecciones hospitalarias por Staphylococcus aureus; meticilino resistente vs meticilino sensible. Rev Panam Infectol 2006; 8:33-38
28. Wang G, Hindler J, Ward K, et al: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin MIcrobiol 2006; 44:3883-3886
29. Kantzanou M, Tassios PT, Tseleni-Kotsovili A, et al: Reduced susceptibility to vancomycin of nosocomial isolates of methicillinresistant Staphylococcus aureus. J Antimicrob Chemother 1999; 43:729-731
30. Van Griethuysen A, van?t Veen A, Buiting A, et al: High percentage of methicillinresistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J Clin Microbiol 2003; 41:2487-2491
31. Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-794